LAUSR

108 Background: Recently, nivolumab has been approval as 2nd-line treatment of non-small cell lung cancer (NSCLC) in our country. Data regarding its effectiveness or safety in real-life setting are publishing daily. Methods: 27 patients with advanced NSCLC treated with nivolumab at HURS between February 2016 to November 2017, were evaluated for survival (overall survival OS, progression-free survival PFS), time to treatment failure (TTF), treatment discontinuation due to toxicity and demographics/clinicopathological characteristics, using SPSS v 8.0. Results: Median age was 62 years; 77,8% males. At closing data, 25,9% of patients were still receiving nivolumab treatment. 51,9 % had finished treatment due to disease progression and 7,4% to toxicity. 25,9% patients continued others chemotherapies schedules. Mean of cycles received was 11. 51,8% presented ORR to nivolumab (78% PR). The median TTF at nivolumab was 3 months. The median progression-free survival (PFS) was 6.93 months (6,2 months in the squamous histology vs 9,42 in adenocarcinoma). The median OS was 22.6 months. Neutrophil-lymphocyte ratio in a complete blood count did not decrease during nivolumab treatment in any patients (p < 0.05, McNemar test), no relation to survival rates (with a cut-off of 5 and 3). Conclusions: Effectiveness (OS and PFS) of nivoumab were high in our patients, slightly better than those observed with similar characteristics included in clinical trials. We have not found predictive survival markers.